scholarly journals Budget Impact Analysis Of Subcutaneous Belimumab In Patients With Systemic Lupus Erythematosus In Spain

2019 ◽  
Vol Volume 11 ◽  
pp. 757-765
Author(s):  
Maria Cevey ◽  
Jaime Calvo-Alén ◽  
Carlos Crespo ◽  
Angel Robles-Marhuenda ◽  
Lee Smolen ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Impact Analysis ◽  
Budget Impact ◽  
Budget Impact Analysis ◽  
Systemic Lupus ◽  
P Budget

scholarly journals Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements

2020 ◽  
Vol Volume 12 ◽  
pp. 233-240 ◽  
Author(s):  
Helen Phillips-Jackson ◽  
Clive Hallam ◽  
Niamh Cullen ◽  
Terry Pearson ◽  
Mark Gilman ◽  
...  
Keyword(s):  
Impact Analysis ◽  
Budget Impact ◽  
Opioid Use Disorder ◽  
Budget Impact Analysis ◽  
Prolonged Release ◽  
Opioid Use ◽  
Resource Requirements ◽  
P Budget

scholarly journals Budget impact analysis of the new reimbursement policy for day surgery in Thailand

2019 ◽  
Vol Volume 12 ◽  
pp. 41-55
Author(s):  
Rapeepong Suphanchaimat ◽  
Jutatip Thungthong ◽  
Kriddhiya Sriprasert ◽  
Kanjana Tisayaticom ◽  
Chulaporn Limwattananon ◽  
...  
Keyword(s):  
Impact Analysis ◽  
Budget Impact ◽  
Day Surgery ◽  
Budget Impact Analysis ◽  
Reimbursement Policy ◽  
P Budget

BUDGET IMPACT ANALYSIS OF BELIMUMAB IN TREATING SYSTEMIC LUPUS ERYTHEMATOSUS

2016 ◽  
Vol 32 (5) ◽  
pp. 348-354 ◽  
Author(s):  
Francesca Pierotti ◽  
Iaria Palla ◽  
Lara Pippo ◽  
Valentina Lorenzoni ◽  
Giuseppe Turchetti
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Disease Progression ◽  
Lupus Erythematosus ◽  
Standard Therapy ◽  
Budget Impact ◽  
National Health System ◽  
Economic Benefits ◽  
European Medicines Agency ◽  
Systemic Lupus ◽  
Damage Accrual

Objectives: The study evaluates the costs of systemic lupus erythematosus (SLE) and the budget impact due to the introduction of belimumab in the Italian setting.Methods: Adaptation to the Italian setting of a budget impact model with a time horizon of 4 years (year 0 without belimumab, years 1–3 with belimumab) to compare treatment, administration, and clinical monitoring costs of standard therapy and of the alternative scenario in which belimumab is administered in addition to the standard therapy to the subgroup of patients selected according to the label approved by the European Medicines Agency. The model takes also into account the costs of flares.Results: Over 3 years, belimumab is able to prevent cumulatively 1,111 severe flares and 3,631 nonsevere flares with a total saving for the Italian National Health System (NHS) of approximately €6.2 million. Budget impact ranges from €4.4 million in the first year to €20.3 million in the third year.Conclusions: The decrease in the number of flare partially counterbalances the costs of the new technology (impact attenuation of approximately 16 percent). These data elucidate the importance to control and monitor the disease progression and to prevent exacerbations, which are the major causes of the increase in costs paid by the NHS and by the society. The financial impact could be replicate on a regional basis, to inform local decision makers. Further developments are possible as the model does not consider the additional clinical and economic benefits of reduced damage accrual and slowed disease progression.

Organized Intraglomerular Deposits in NZB Mouse Disease

1971 ◽  
Vol 29 ◽  
pp. 544-545
Author(s):  
Francis R. Comerford ◽  
Alan S. Cohen
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Antinuclear Antibodies ◽  
Human Systemic Lupus Erythematosus ◽  
Systemic Lupus ◽  
Glomerular Lesion ◽  
Ultrastructural Studies ◽  
Dense Deposits ◽  
Experimental Nephritis ◽  
Glomerular Lesions

Mice of the inbred NZB strain develop a spontaneous disease characterized by autoimmune hemolytic anemia, positive lupus erythematosus cell tests and antinuclear antibodies and nephritis. This disease is analogous to human systemic lupus erythematosus. In ultrastructural studies of the glomerular lesion in NZB mice, intraglomerular dense deposits in mesangial, subepithelial and subendothelial locations were described. In common with the findings in many examples of human and experimental nephritis, including many cases of human lupus nephritis, these deposits were amorphous or slightly granular in appearance with no definable substructure.We have recently observed structured deposits in the glomeruli of NZB mice. They were uncommon and were found in older animals with severe glomerular lesions by morphologic criteria. They were seen most commonly as extracellular elements in subendothelial and mesangial regions. The deposits ranged up to 3 microns in greatest dimension and were often adjacent to deposits of lipid-like round particles of 30 to 250 millimicrons in diameter and with amorphous dense deposits.

“Subcortical” cognitive impairment in patients with systemic lupus erythematosus

2000 ◽  
Vol 6 (7) ◽  
pp. 821-825 ◽  
Author(s):  
ELIZABETH LERITZ ◽  
JASON BRANDT ◽  
MELISSA MINOR ◽  
FRANCES REIS-JENSEN ◽  
MICHELLE PETRI
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Cognitive Impairment ◽  
Lupus Erythematosus ◽  
Systemic Lupus
Sign in / Sign up

Export Citation Format

Share Document